1 Min Read
March 8 (Reuters) - Inflarx Nv:
* INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.